江苏联环药业股份有限公司股票交易异常波动的公告

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. experienced significant stock price fluctuations, with a cumulative closing price increase exceeding 20% over three consecutive trading days in early August 2025, prompting an announcement regarding abnormal trading activity [2][3]. Summary by Sections Stock Trading Abnormality - The company's stock price increased by over 20% cumulatively on August 1, 4, and 5, 2025, which is classified as abnormal trading activity according to the Shanghai Stock Exchange rules [2][3]. Company Operations and Major Events - A self-inspection revealed that the company's production and operations are normal, with no significant changes in market conditions or internal operations [4]. - The company confirmed that there are no undisclosed major events, such as asset restructuring or significant transactions, involving its controlling shareholders or actual controllers [5]. Media Reports and Market Rumors - The company found no significant events that could impact its stock price, nor any media reports or market rumors that require clarification [6]. Other Price-Sensitive Information - No other major events that could significantly affect the company's stock price were identified, and there were no stock trading activities by the controlling shareholders or management during the abnormal trading period [7]. Financial Performance - The company expects a net profit loss for the first half of 2025, estimating a range of -45 million to -38 million RMB, representing a decrease of 100.89 million to 107.89 million RMB compared to the same period last year, indicating a shift from profit to loss [2][12].